Drugs / AeroFact
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06367881 | Aug 2022 → Jul 2024 | inflammatory disease, pulmonary immaturity, respiratory distress syndrome in premature infants | Ain Shams University | Unknown | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT03969992 | Mar 2020 → Aug 2023 | respiratory distress syndrome in premature infants | Aerogen Pharma Limited | Completed | Missed primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT06776783 | Sep 2025 → May 2027 expected | respiratory system disorder | Aerogen Pharma Limited | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AeroFact | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03969992 ↗ |
| Known as | Alveofact | “This study investigated whether exogenous surfactant (Alveofact) combined with intratracheal budesonide modulates these pathways.” PMID 41872545 ↗ Mar 2026 |
| Known as | SF-RI 1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06776783 ↗ |
| Modality | Other / unclassified | “exogenous surfactant (Alveofact)” PMID 41872545 ↗ Mar 2026 |
| Route | Other | “when delivered via nCPAP” NCT03969992 ↗ |